Last reviewed · How we verify
No mesenchymal progenitor cells
At a glance
| Generic name | No mesenchymal progenitor cells |
|---|---|
| Sponsor | Shanghai AbelZeta Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss (PHASE1, PHASE2)
- The Safety and Efficacy of XytriX in the Treatment of Knee Osteoarthritis (PHASE1, PHASE2)
- Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) (PHASE2)
- Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure (PHASE1)
- Aerosolized Mesenchymal Stem Cell-Derived Exosomes for the Prevention and Treatment of Radiation-Induced Oral Mucositis (PHASE2)
- Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells (PHASE1, PHASE2)
- A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD (PHASE2)
- Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- No mesenchymal progenitor cells CI brief — competitive landscape report
- No mesenchymal progenitor cells updates RSS · CI watch RSS
- Shanghai AbelZeta Ltd. portfolio CI